JPRN-jRCT2080221437未知3 期
An open-label Phase 3 study of S-474474 in patients with essential hypertension - Evaluation of the safety and efficacy of long term use
适应症
试验速览
- 阶段
- 3 期
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 79age old（—）
- 性别
- All
入选标准
- •Patients with essential hypertension who meet the following criteria:
- •Untreated patients whose seated systolic blood pressure is not less than 160 mmHg, or seated diastolic blood pressure is not less than 100 mmHg, and systolic blood pressure is lower than 180 mmHg, and diastolic blood pressure is lower than 110 mmHg, etc.
排除标准
- •Patients with renal, hepatic or heart disease
研究者
相似试验
未知
3 期
A randomized, double-blind Phase 3 study of S-474474 in patients with essential hypertension, - Evaluation in non-responder to irbesartanHypertensionJPRN-jRCT2080221107SHIONOGI & CO., LTD.
未知
3 期
A Phase 3 study of S-474474 in patients with essential hypertensioHypertensionJPRN-jRCT2080221505SHIONOGI & CO., LTD.
已完成
2 期
A phase 2, open-label study of S-646240 in patients with age-related macular degeneration accompanied by choroidal neovascularizatioAge-related macular degenerationJPRN-UMIN000008040Shionogi & Co., Ltd.40
未知
3 期
Phase 3 open-label study of OPC-41061 in subjects with cardiac-induced edema (congestive heart failure) - an investigation of the safety of treatment beyond 7 days and the effect of dose escalation to 30 mgJPRN-jRCT2080220454Otsuka Pharmaceutical Co., Ltd.
进行中（未招募）
不适用
A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe DiseasePompe disease (acid alpha-glucosidase deficiency)MedDRA version: 17.1Level: LLTClassification code 10036143Term: Pompe's diseaseSystem Organ Class: 100000004850EUCTR2015-000512-18-Outside-EU/EEAGenzyme Corporation Inc114